PhoreMost Ltd
PhoreMost™ is focused on bringing more effective and affordable targeted medicines to patients. To achieve this aim, PhoreMost is developing a next-generation phenotypic screening technology that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the company's proprietary Protein Interference (PROTEINi®) technology, PhoreMost has developed SITESEEKER®; a platform that can systematically unmask cryptic druggable sites in the human genome and then link them to useful therapeutic functions in a live-cell context.